Drug discovery and development targeting the life cycle of SARS-CoV-2
A newly emerged coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), belongs to the β-coronavirus family and shows high similarities with SARS-CoV. On March 11, 2020, the World Health Organization (WHO) declared SARS-CoV-2 a global pandemic, and the disease was named the corona...
Main Authors: | Haixia Su, Yechun Xu, Hualiang Jiang |
---|---|
Format: | Article |
Language: | English |
Published: |
KeAi Communications Co. Ltd.
2021-03-01
|
Series: | Fundamental Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S266732582100025X |
Similar Items
-
SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
by: Hatem A. Elshabrawy
Published: (2020-06-01) -
Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
by: Sicong Yu, et al.
Published: (2021-06-01) -
Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease
by: Qian Wang, et al.
Published: (2023-05-01) -
Neutralizing and enhancing antibodies against SARS-CoV-2
by: Yafei Liu, et al.
Published: (2022-12-01) -
Fast-Track Discovery of SARS-CoV-2-Neutralizing Antibodies from Human B Cells by Direct Functional Screening
by: Matthias Hillenbrand, et al.
Published: (2024-02-01)